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Intravenous immunoglobulins (IVIGs) have not yet demonstrated robust evidence in the benefit for treatment of
sepsis. In spite of multiple clinical trials performed with IVIG in sepsis, it remains an experimental therapy for this
severe condition. Nonetheless, these trials do not address a number of potential confounding factors, concerning
both the patient and the IVIG preparations, which could greatly affect the final result. To name a few, endogenous
levels of immunoglobulin isotypes and subclasses are not assessed prior to treatment. The presence/absence
of patient antibodies against the microorganism(s) causing sepsis is not evaluated. The accuracy of antibiotic
prescription is not included as an adjusting variable. The degree of patient immunosuppression (previous or
induced by sepsis) is not documented. In turn, the concentration and antimicrobial specificities of the antibodies
contained in the batches of IVIG are not assessed. Neither the pharmacokinetics of IVIG nor its potential
immunomodulatory effects are evaluated. In addition, the concept of ‘window of opportunity’ for IVIG
administration following diagnosis of sepsis is not considered. In conclusion, addressing these factors could help to
individualise treatment with IVIG for sepsis, which could enhance the opportunities of this drug to show benefits in
terms of survival in this severe condition.Introduction
Mortality associated with severe sepsis and septic shock
ranges from 20% to 30% [1]. Many different approaches
tested for treating this disease failed to improve survival
[1]. The presence of low levels of immunoglobulins (Igs)
in serum is a frequent finding in severe sepsis and septic
shock, ranging from 25% to 61% of the patients in the
case of IgG and 19% to 33% for IgM [2-4]. Nonetheless,
results from clinical trials evaluating exogenous Igs for
treatment of this disease are controversial [5,6]. A meta-
analysis published in 2013 concluded that there was a
protective effect of polyclonal intravenous immunoglob-
ulins (IVIGs) against mortality among adults with sepsis,
which was not seen in trials with low risk of bias [5]. In
contrast, Kreymann and colleagues [7] reported that the
mortality-reducing effect of IVIG was also seen in trials
with the highest methodological quality. In our view,
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factors that could greatly affect the final result (Figure 1).Factors related to the patient
The influence of endogenous levels of immunoglobulins
The influence of endogenous levels of Igs on prognosis
remains unclear. Whereas the SBITS (Score-Based Im-
munoglobulin Therapy of Sepsis) study [8] did not show
any negative influence of a low IgG level on 28-day mor-
tality [2], Taccone and colleagues [9] found that patients
with community-acquired septic shock and hypo-IgG
had higher mortality. Similarly, Průcha and colleagues
[10] reported the presence of IgG hypogammaglobuline-
mia in patients with severe sepsis as an independent fac-
tor of mortality. In turn, we have recently demonstrated
the existence of a statistical association between low en-
dogenous levels of Igs and poor outcome in severe sepsis
and septic shock [4]. Differences among studies could be
explained in part by the different composition of the pa-
tient cohorts. In the SBITS study, percentile 25 for IgG
distribution was 610 mg/dL, whereas in our study it was
374 mg/dL, probably because of a higher frequency ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Potential confounding factors not appropriately considered in the design or analysis of the clinical trials evaluating IVIG for the
treatment of sepsis. Main factors are in bold. Other factors related to them are in standard type. IVIG, intravenous immunoglobulin; NK, natural killer.
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cohort (Werdan K, personal communication). Although it
remains to be elucidated whether low levels of endogen-
ous Igs are a marker of disease severity rather than a cause
of mortality, our opinion is that it is a potential confound-
ing factor that has to be taken into account in the IVIG
trials. In addition, the distinct Ig subclasses and isotypes
(IgG1, IgM, and IgA) have a different influence on prog-
nosis in sepsis [4]. Combined deficits of these isotypes are
associated with higher risk of mortality [4]. Assessing
levels of basal Ig isotypes could help us to understand the
potential effect of IVIG preparations containing only IgG
and of those enriched in IgM or IgA or both. It could be
also important to evaluate the presence/absence of pre-
existing specific antibodies against the microbe causing
the septic insult [11].Accuracy of antibiotic prescription
Early administration of an appropriate antibiotic treat-
ment, along with life support measures, is the only
treatment that has been demonstrated to improve sur-
vival in sepsis [1]. Therefore, the accuracy of antibiotic
treatment could greatly influence the results of IVIG. In
this sense, the application of new proteomics and gen-
omics methods is translating into an earlier and moreexact microbiological diagnosis, which in turn will help
to optimise antibiotic prescription in sepsis [12].
Evaluation of the basal degree of immunosuppression
Sepsis is often associated with the presence of immunosup-
pression. This condition could greatly affect levels of en-
dogenous Igs but also levels or function of other elements of
the immune system which are very important for achieving
infection control (antigen presentation, interferon response,
T cells, natural killer cells, neutrophils, and complement fac-
tors) [13,14]. Quantitative and qualitative evaluation of these
elements could help to obtain a good picture of the basal
immunological status of the patient receiving IVIG.
Factors related to intravenous immunoglobulin
Intravenous immunoglobulin composition
IVIG content in Ig isotypes could influence trials results.
This way, IgM-enriched IVIG could render more benefits
in terms of survival than those preparations containing
just IgG [5,7]. Another major issue is the absence of evi-
dence characterising the primary therapeutic principles in
IVIG (Fab elements ?, Fc fragments ?) which could have
potentially beneficial effects in sepsis (toxin scavenging,
antibacterial effect, and immunomodulation) [6]. More-
over, the concentration and antimicrobial specificities of
the antibodies contained in the IVIG preparations are not
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on the personal antecedents of natural infections and vac-
cination of the blood donors for IVIG, who are healthy in-
dividuals. In consequence, IVIG could be deficient in
antibodies against microbes causing hospital-acquired in-
fections. Developing new IVIG preparations obtained from
pools of sera of survivors to sepsis of either community or
nosocomial origin could solve this problem. In addition,
taking into account the age of the blood donors could be
important for understanding the biological properties of
IVIG since the natural IgG Ig repertoire is highly dependent
on age.
Dosage, timing, and pharmacokinetics of intravenous
immunoglobulin
There is probably a ‘window of opportunity’ for IVIG in
the first days that follow clinical presentation of sepsis
[15]. If this window is missed, probabilities of success
could be greatly diminished. In addition, monitoring Ig
levels along the course of the treatment would help us
to understand the pharmacokinetics of IVIG in patients
with sepsis which is relevant for further dosage calcula-
tion. In turn, it is unknown whether the main goal of
IVIG in sepsis has to be to refill low levels of endogen-
ous Igs or alternatively whether IVIG could exert a
beneficial effect independently of these levels. Some of
the factors listed above are difficult to assess at the mo-
ment a patient is included into a clinical trial but could
be assessed afterwards, in the phase of data analysis.
Conclusions
Addressing the factors exposed here could help us to indi-
vidualise treatment with IVIG for sepsis and in turn to en-
hance the opportunities of this treatment to show benefits
in terms of survival in this severe condition.
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